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 Streptococcus pneumoniae (the pneumococcus) is the leading cause of community-acquired pneu-
monia. The incidence of pneumococcal pneumonia 
is greatest at the extremes of age and in individuals 
with medical comorbidity. Pneumococcal infection 
causes approximately 2 million deaths globally and 
costs hundreds of billions of dollars per annum. 
 Streptococcus pneumoniae frequently colonizes the 
nasopharynx and from the nasopharynx, pneumococci 
can spread directly via the airway to the lower respi-
ratory tract, causing pneumonia, or to the sinuses or 
middle ears, causing medical morbidity. Bacteria may 
also penetrate the epithelial cell surface, resulting in 
local infection or bacteremia. The pleura and menin-
ges can be seeded by local spread of infection or by 
bacteremia. Invasive pneumococcal disease (IPD) is 
deﬁ ned as isolation of bacteria from a normally ster ile 
site, such as blood, cerebrospinal ﬂ uid, or pleural space, 
and results from invasion of the respiratory epithelium. 
 Antimicrobial therapy and vaccination have been cen-
tral to the clinical approach to pneumococcal dis ease, 
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 Vaccination and antimicrobial therapy remain the cornerstones of the management of pneumo-
coccal pneumonia. Despite signiﬁ cant successes, the capacity of the pneumococcus to evolve in 
the face of the selective pressure of anticapsular immunity challenges immunization programs. 
Treatment focuses on antimicrobial therapy but ignores the central role of the dysregulated 
inﬂ ammatory response during pneumonia. Future therapeutic approaches need to build on 
the considerable recent advances in our understanding of the pathogenesis of pneumococcal 
pneumonia, including those from models of pneumonia. Enhancement of the essential compo-
nents of the host response that prevents most colonized individuals from developing pneumonia 
and strategies to limit inappropriate inﬂ ammatory responses to lower respiratory tract infection 
are approaches that could be exploited to improve disease outcome. This review highlights recent 
discoveries relating to the microbial and host determinants of microbial clearance and regulation 
of the inﬂ ammatory response, which provide clues as to how this could be achieved in the future. 
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but efforts to enhance the host response, other than 
through immunization, have received limited attention. 
This is somewhat surprising because colonization 
with the pneumococcus is widespread and develop-
ment of pneumonia is a comparatively rare event. 
This review focuses on recent ﬁ ndings relating to 
the microbiology and pathogenesis of pneumococcal 
pneumonia and includes data from murine models 
of pneumococcal disease. Murine models of pulmo-
nary infection have provided valuable insights because 
they have allowed the manipulation of molecules or 
speciﬁ c cell populations to test their role in a model 
system of pneumococcal pneumonia. 
 Genetic Variation 
 Streptococcus pneumoniae demonstrate transfor-
mation and horizontal gene transfer, ensuring a high 
rate of variation in the genome. Pneumococci acquire 
environmental DNA from a number of sources, includ-
ing the extracellular matrix of pneumococcal bioﬁ lms, 
which contain DNA,  1  and via microbial fratricide, 
whereby noncompetent siblings are lysed, facilitating 
release of chromosomal DNA.  2  The “distributed-
genome hypothesis” posits that pathogenic bacteria 
have a large number of noncore genes (the “bacterial 
supragenome”) not present in all strains, maintaining 
diversity. Analysis of eight pneumococcal strains col-
onizing children, and comparison with nine freely 
available strains, revealed that 54% of genes were 
not found in all strains and that any individual strain 
possessed only 21% to 32% of these noncore genes.  3  
Whole genome sequencing of 240 isolates of serotype 
23F, strains associated with multidrug antimicrobial 
resistance, has revealed that 74% of the genome 
was altered in at least one of the sequenced strains.  4  
Recombination hot spots were not just related to 
genes encoding antimicrobial targets, but were also 
concentrated in genes encoding capsular biosynthesis 
and adhesins, targets of the immune response. These 
ﬁ ndings suggest that current vaccine strategies provide, 
and future vaccine strategies should provide, a potent 
selective pressure for pneumococcal genetic evolution 
and that pneumococci will likely continue to evolve in 
response to the selective pressure exerted both by the 
immune response to vaccines and by antimicrobials. 
 Capsule Diversity 
 At least 92 different serotypes of pneumococcal 
polysaccharide capsule exist, the most recently described 
being serotype 11E.  5  A systematic review and meta-
analysis compared the risk of death with speciﬁ c 
serotypes, using serotype 14 as the reference strain.  6  
Results were compared with adults with low comor-
bidity scores to reduce confounding by host factors. 
Serotypes associated with an increased risk of death 
during bacteremic pneumonia included serotypes 3, 
6A and B, 9N, and 19F, whereas serotypes 1, 7F, and 
8 were associated with a lower risk of death. The 
serotypes associated with an increased risk of death 
were those strains that cause lower rates of IPD fol-
lowing pediatric colonization.  7  These strains are less 
likely to invade but when they do, IPD results in 
a higher mortality than observed for other strains 
( Table 1 ). Colonizing strains behave as “opportunistic 
infections” in individuals with medical comorbidi-
ties, whereas strains with a higher propensity to cause 
IPD when carried in the nasopharynx behave as “pri-
mary pathogens” in medically ﬁ t individuals.  11  
 The ability of pneumococci to colonize and invade 
has been related to a variety of factors, including 
phase variation. In this process, the colony morphol-
ogy for an individual serotype can vary between trans-
parent and opaque when viewed on transparent agar 
with oblique transmitted light. Transparent pheno-
types colonize the airway readily, whereas opaque 
phenotypes are well able to survive in the blood-
stream and resist phagocytosis.  12  Opaque phenotypes 
have a number of characteristics favoring survival 
following tissue invasion, one of which is the pres-
ence of increased encapsulation.  13  
 Table 1 —Inﬂ uence of Capsular Serotype on Clinical Course and Biologic Behavior 
 Study Characteristic
Serotypes Associated With 
Colonization and Impact (Relative 
to Reference Strain if Applicable)
Serotypes Associated With 
Increased Rates of IPD Studied and 
Impact Relative to Reference Strain 
 Weinberger et al  6  Mortality with IPD   with 3, 6A, 6B, 9N, and 19F vs 14 a   with serotype 1, 7F and 8 vs 14 
 Weinberger et al  8  Resistance to nonopsonic 
 killing by neutrophils
  with 6A, 6B, 9N, 14,  a  19F, and 23F vs 9V   with serotype 1, 4, 5 vs 9V 
 Sanchez et al  9  Accessibility of adhesins    6A, 23F    4 
 Sanchez et al  9  Ingestion by alveolar macrophages    6A, 23F    4 
 Hyams et al  10  Deposition of complement    6A, 23F    4, 7 
 Weinberger et al  8  Capsule   with 6A, 6B, 19F, and 23F vs 9V   with serotype 1, 4, 5, 7 and 14 a vs 9V 
 Serotypes of  Streptococcus pneumoniae were grouped as either associated with colonization and relatively low rates of IPD per 100,000 acquisition 
events or as being associated with relatively high attack rates of IPD per 100,000 colonizing events, as described by Sleeman et al  7  in a pediatric 
population, and the relative frequency of various characteristics compared. IPD  5 invasive pneumococcal disease. 
 a The behavior of serotype 14 has some features of strains associated with low and some features associated with high attack rates. 
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 Differences in the capsule among serotypes are 
also an important determinant of the variation in bio-
logic behavior among serotypes. Colonizing strains 
are more resistant to nonopsonic killing by neutro-
phils,  8  a key determinant of nasopharyngeal car-
riage.  14  Capsular switch studies, in which different 
serotype capsules are swapped onto an otherwise 
identical genetic background, conﬁ rm that differences 
in capsule account for much of the variation in bio-
logic behavior. Capsular serotype also inﬂ uences 
tissue invasion; serotype 6A or 23F capsule is associ-
ated with reduced accessibility of adhesins, including 
pneumococcal surface protein, choline-binding pro-
tein A, and pneumococcal serine-rich repeat protein 
(PsrP), resulting in decreased adherence to epithelial 
cells and increased ingestion by alveolar macrophages 
(AMs), when compared with the more invasive sero-
type 4 capsule.  9  Capsules from invasive serotypes, 
such as serotype 4 and 7F, are more resistant to com-
plement deposition and opsonin-dependent phago-
cytosis than are capsules associated with colonization, 
such as 6A and 23F,  10  although variation in comple-
ment deposition is not mediated solely by capsular 
serotype.  15  
 Thus, colonizing and invasive strains have evolved 
to exploit unique ecologic niches and have acquired 
the necessary adaptations to evade the key immune 
responses controlling bacterial replication in their 
location ( Fig 1 ). The colonizing strains with reduced 
invasive potential escape nonopsonic neutrophil-
dependent phagocytosis but, when they do translocate 
into the distal airway, are more easily cleared by AMs 
and more readily cleared in the lung or bloodstream 
by complement-dependent mechanisms. This may 
explain why they less commonly cause invasive disease. 
In contrast, the strains of greater invasive potential 
are readily cleared from the upper airway by neutro-
phils but if they escape neutrophil-mediated clear-
ance they can more easily bind to epithelial cells via 
adhesins and translocate across the epithelium, as sug-
gested by Weinberger and colleagues.  8  They are also 
more resistant to AM- and complement-mediated clear-
ance, explaining their relative success as invasive strains. 
 Strains associated with colonization have thicker 
capsules produced at lower metabolic cost.  8  Serotype 
replacement is a well-recognized phenomenon after 
protein conjugate vaccination,  19  and colonizing cap-
sular serotypes that evolve with the selective pres-
sure of vaccination are predicted to be those with the 
larger and less metabolically costly capsules.  8  
 Recognition of the Toxin Pneumolysin 
 A cholesterol-dependent cytolysin named pneumo-
lysin is a critical virulence factor for pneumococci,  18  
but recent work has highlighted that both the direct 
effects of the toxin on cells and the immune response 
to the toxin may inﬂ uence pathogenicity. Moreover, 
an increasing number of pattern-recognition recep-
tors are shown to be involved in the innate immune 
response to pneumolysin. The capacity of pneumo-
lysin to form membrane pores that lyse cells and to 
activate complement T cells, neutrophils, or macro-
phages at sites of infection is well established. Recent 
attention has focused on the pattern-recognition recep-
tors involved in sensing pneumolysin. 
 Toll-like receptor (TLR ) 4 was the ﬁ rst pattern rec-
ognition identiﬁ ed to interact with pneumolysin.  20  
However, not all innate responses could be linked to 
TLR4 engagement; a recent study identiﬁ ed TLR4-
independent pneumolysin responses, including den-
dritic cell activation and production of interferon 
(IFN)- g and IL-17A by T cells. This study noted the 
ability of pneumolysin to synergize with TLR engage-
ment to stimulate cytokine production by macro-
phages and dendritic cells.  21  Pneumolysin stimulated 
caspase-1-dependent processing of IL-1 b , which is 
required to secrete the leaderless protein IL-1 b . The 
authors observed PLY-dependent caspase-1 activa-
tion is dependent on the nucleotide-binding oligo-
merization domain (Nod)-like receptor (NLR) P3 
inﬂ ammasome and the apoptosis-associated speck-
like protein containing a caspase recruitment domain 
(ASC) adaptor protein ( Fig 2 ), 22  thus implicating a 
pattern-recognition receptor other than TLR4 in pneu-
molysin recognition. The authors also established a 
requirement for pore formation by pneumolysin and 
activation of the lysosomal protease cathepsin B for 
IL-1 b release. 
 These results have been extended by another group, 
who showed that a number of strains of pneumococci 
that express a pneumolysin, which lacks pore-forming 
activity, are impaired in their capacity to induce 
NLRP3-dependent IL-1 b secretion.  25  These strains 
include the highly prevalent serotype 1 strain ST306, 
which causes empyema and disease outbreaks. These 
ﬁ ndings suggest that some strains’ success at causing 
invasive disease is related to their capacity to evade 
pattern-recognition receptors such as NLRP3. They 
also suggest, however, that the lower mortality asso-
ciated with these strains might be linked to their 
lower potential to induce proinﬂ ammatory responses. 
The highly virulent serotype 1 strain 4496 (ST3018, 
lineage C) expresses pneumolysin of reduced hemo-
lytic potential, which shares some of the mutations 
associated with other strains of reduced pore-forming 
activity but also has some unique mutations.  26  In a 
murine model of invasive disease, a mutant-expressing 
pneumolysin from strain 4496 resulted in increased 
levels of bacteremia in the ﬁ rst 15 h of infection but 
also increased survival as compared with an isogenic 
mutant-expressing toxin of full hemolytic potential. 
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 Figure 1.  Pneumococcal virulence factors inﬂ uencing colonization and invasion. CSTs and ISTs of 
Spn show distinct characteristics, which are in part deﬁ ned by polysaccharide capsule.  8  CSTs are more 
readily coated with COMP, but ADHs, including pneumococcal surface protein A, choline-binding 
protein A, and PsrP, are more accessible in ISTs. In the URT, the CSTs are likely to colonize in part 
because when nonopsonized they are less susceptible to PMN. In contrast, CSTs are readily phagocy-
tosed by AMs in the LRT and are less likely to cause invasive disease. ISTs less readily colonize the URT 
and are more likely to adhere to ECs and penetrate tissue, ultimately reaching BVs and establishing 
bacteremia. ISTs are also more resistant to phagocytosis by AMs. Independent of the capsule, PsrP will 
favor bioﬁ lm formation  16  and resistance to AM phagocytosis, whereas production of pili and PsrP will 
enable attachment to epithelia.  17  Pili  17  and PLY  18  will also inﬂ uence invasion and ampliﬁ cation of the 
inﬂ ammatory response. ADH  5 adhesin; AM  5 alveolar macrophage; BV  5 blood vessel; COMP  5 com-
plement; CST  5 colonizing serotype; EC  5 epithelial cell; IST  5 invasive serotype; LRT  5 lower respi-
ratory tract; PLY  5 pneumolysin; PMN  5 phagocytosis by neutrophils; PsrP  5 pneumococcal serine-rich 
repeat protein; Spn  5  Streptococcus pneumoniae ; URT  5 upper respiratory tract 
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In murine models, NLRP3-associated responses 
enhanced pulmonary clearance of pneumococci from 
the lung and moderately reduced lung injury and 
mortality.  21 , 25  Another group have suggested that the 
impairment in IL-1 b and IL-18 secretion and the 
host response to pneumolysin is more markedly per-
turbed in the absence of ASC, as opposed to NALP3, 
and have implicated a further inﬂ ammasome receptor 
that also uses ASC, absent in melanoma 2, as contrib-
uting to the host response to pneumolysin.  27  In con-
clusion, NALP3 and potentially other inﬂ ammasome 
receptors have emerged as important mediators of 
host immunity to pneumococci. Strains that do not 
engage this recognition system may have a survival 
advantage that facilitates their spread into the blood-
stream but, once in this location, their reduced capac-
ity to generate inﬂ ammatory responses may result in 
improved survival. 
 Additional Virulence Determinants 
 Multiple other virulence factors contribute to 
pneumococcal pathogenesis.  28 , 29  Two recent ﬁ ndings 
merit emphasis. PsrP is a pathogenicity island-encoded 
adhesin, which has emerged as contributing to lower 
respiratory tract virulence and in binding to the lung 
  
 Figure 2.  Pattern-recognition receptors involved in the recognition of Spn. A variety of Spn-derived 
factors can stimulate TLRs expressed both on the cell surface and on phagolysosome membranes. TLR2 
recognizes LPs, TLR4 PLY and TLR9 unmethylated CpG dinucleotides in bacterial DNA.  22  The release 
of factors can be aided by digestion of bacterial components by lysosomal enzymes. In addition, some 
digested fragments may be released from a pPL and engage cytosolic pattern-recognition receptors 
such as MDP, which engages Nod2.  23  PLY also activates the NALP3 INF containing the ASC adaptor 
protein,  21  and potentially other inﬂ ammasomes, although the mechanism of release of these factors 
from the phagolysosme awaits clariﬁ cation and it is not clear if the release is selective or part of a more 
generalized permeabilization event. Bacterial DNA (Spn DNA) released from the phagolysosme is rec-
ognized by DAI in the cytoplasm.  24  ASC  5 apoptosis-associated speck-like protein containing a caspase 
recruitment domain; DAI  5 DNA-dependent activator of interferon regulatory factors; INF  5 inﬂ am-
masome; LP  5 lipopeptide; MDP  5 muramyl dipeptide; NALP3  5 nucleotide-binding oligomerization 
domain-like receptor; Nod  5 nucleotide-binding oligomerization domain; Nod2  5 nucleotide-binding 
oligomerization domain-containing protein 2; pPL  5 permeabilized phagolysosome; TLR  5 toll-like 
receptor. See Figure 1 legend for expansion of other abbreviations. 
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epithelium but does not contribute to colonization 
or sepsis. Recently, PsrP has emerged as playing an 
important role in bacterial aggregation and the matu-
ration of bioﬁ lms.  16  Murine models demonstrate bio-
ﬁ lm formation in the lung, and mutants lacking PsrP 
induce less bioﬁ lm formation, potentially impacting 
bioﬁ lm-mediated resistance to phagocytosis and to 
antimicrobials. The second ﬁ nding relates to another 
pathogenicity island-expressed vir ulence factor, the 
production of pili. Pili were not recognized as viru-
lence factors in pneumococci until relatively recently 
and are only expressed by certain strains.  17  Their 
expression, however, enables bacteria to survive in the 
lung and to bind to epithelial cells. In addition, pili-
ated strains trigger a greater tumor necrosis factor -
dependent inﬂ ammatory response, with the potential 
to cause lung injury and facilitate tissue invasion. 
 Control of Colonization 
 Upper airway colonization is thought to precede the 
development of pneumonia. Colonization is, however, 
a frequent event in comparison with pneumonia and 
in most cases does not lead to the development of 
clinical disease. T helper cell (Th)17 T-cell responses 
are key in clearing colonizing bacteria.  14  The phago-
cytic effectors of Th17 T-cell-dependent bacterial 
clearance will, however, vary, depending on whether 
the host has been previously exposed to pneumo-
cocci. In naive mice, recruitment of macrophages 
aids clearance of colonizing bacteria, whereas in mice 
with prior colonization, neutrophils mediate more 
rapid bacterial clearance. Key events in the innate 
recognition of colonizing bacteria have also been 
deﬁ ned. Nod2-mediated recognition of peptidoglycan 
fragments degraded by lysozyme M is critical for 
macrophage-mediated clearance of colonizing pneu-
mococci and enables CCL2 chemokine production 
and recruitment of further macrophages.  23  The mac-
rophage response also requires the presence of pore-
forming pneumolysin, and Davis and colleagues 23  
suggested that this could aid the cytosolic translo-
cation of peptidoglycan fragments into the cytosol. 
TLR2, which recognizes lipopeptides expressed by 
pneumococci, made a smaller but additional contribu-
tion to CCL2 production. Nod2-dependent responses 
were also required for the development of Th17 
responses and for adaptive immune responses to col-
onizing bacteria. 
 Type 1 IFN signaling reduces pneumococcal car-
riage because IFN- a / b receptor knockout mice are 
more heavily colonized with pneumococci compared 
with wild-type control mice.  24  Type 1 IFN signaling is 
initiated by pneumococcal DNA that gains access to 
the cytosol via pore formation by pneumolysin and 
activates IFN- b production via the cytosolic sensor 
DNA-dependent activator of IFN regulatory factors. 
Inﬂ uenza A virus triggers a synergistic enhancement 
of type 1 IFN to that produced during pneumococcal 
colonization, and this can inhibit the macrophage-
driven CCL2 response required to clear colonizing 
bacteria.  30  These studies illustrate how sensing of bac-
teria by a range of pattern-recognition receptors (eg, 
TLR2, Nod2, DNA-dependent activator of IFN regu-
latory factors) in the upper airway leads to Th17 and 
type 1 IFN responses and clearance of bacteria by 
macrophages and neutrophils. They also provide clues 
as to how viral infections can subvert innate responses to 
colonizing bacteria (eg, by inhibiting the early CCL2-
dependent macrophage responses). TLR responses 
to colonization can, however, modify epithelial integ-
rity, favoring translocation of bacteria. Recent work has 
shown that p38 mitogen-activated protein kinase - and 
transforming growth factor - b -mediated responses lead 
to upregulation of SNAIL1, a transcriptional repres-
sor of claudin-7 and claudin-10, which are required 
to maintain epithelial cell tight junctions.  31  This illus-
trates the key concept that the inﬂ ammatory response 
must be carefully matched to the host’s requirements 
and that, although underproduction of key cytokines 
can hinder bacterial clearance, excessive production 
can favor tis sue invasion and paresis of key effector 
functions, including phagocytosis. 
 Optimizing Macrophage Effector Functions 
 Colonization and microaspiration of upper airway 
contents are frequent events, and clearance of colo-
nizing bacteria can take a few weeks.  14  The compara-
tive infrequency of pneumonia suggests that efﬁ cient 
host responses must operate in the lower airway to 
protect against pneumonia. A number of components, 
including the cough reﬂ ex, the mucociliary escalator, 
and mucous and humoral factors in the lower air-
way, protect the airway from bacteria; however, cell-
mediated host defense is critical. AMs are the resident 
phagocytes that clear bacteria from the lower airway 
and clear ﬁ nite numbers of bacteria when these reach 
the lower airway.  32  The capacity of the AMs to clear 
bacteria can be overwhelmed in the face of medical 
comorbidities that alter their clearance capacity for 
bacteria, such as COPD.  33  They are also compromised 
by coexistent viral infections, in particular HIV.  34  Fac-
tors such as cigarette smoking that result in alternative 
as opposed to classic activation of AMs also compro-
mise the macrophages’ capacity to clear bacteria.  35  
 Differentiated tissue macrophages have a large lyso-
somal compartment  36  and, when the killing capacity 
of AMs is exhausted, lysosomal permeabilization and 
activation of cathepsin D leads to apoptosis-associated 
killing of bacteria.  37  Cathepsin D activation leads 
to a reduction in protein translation and enhanced 
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proteasomal degradation, with the result that levels 
of proteins with short half-lives, such as a key reg-
ulator of macrophage survival, the antiapoptotic pro-
tein Mcl-1, are reduced, allowing induction of AM 
apoptosis.  37 , 38  Bacterial killing in AMs undergoing 
apoptosis involves reactive oxygen species (ROS) and 
nitric oxide (NO) and occurs at a stage when con-
ventional microbicidal killing has become exhausted. 
Enhancement of the conventional mechanisms of 
intracellular killing, such as the generation of NO via 
inducible NO synthase, reduces the requirement for 
apoptosis-associated killing and can be achieved in 
animal models by administration of granulocyte -
macrophage colony-stimulating factor.  39  Thus, it seems 
that apoptosis-associated killing becomes essential 
in settings in which the macrophages’ capacity to con-
trol ingested bacteria is stressed and ensures a bacte-
rial clearance process, minimizing the inﬂ ammatory 
response.  37  Enhancement of the AM capacity to 
clear bacteria is, therefore, an attractive, but so far 
unexploited, aspect of the therapeutic approach to 
pneumonia. 
 Controlling Neutrophilic Inﬂ ammation 
 If the initial inoculum of bacteria cannot be con-
tained by AMs and other elements of the lung’s innate 
host defenses, then neutrophils are recruited to con-
trol bacterial replication. Macrophages and epithelial 
cells co-operate to generate CXC chemokines and 
other factors that activate a neutrophilic response 
( Fig 3 ).  40,43  Although neutrophils are potent effec-
tors of bacterial clearance, their recruitment results 
in the clinical features of pneumonia and runs the 
risk of causing lung injury. There is considerable 
scope, therefore, to manipulate neutrophilic inﬂ am-
mation during pneumococcal pneumonia. Neutro-
phil recruitment during pneumococcal infection requires 
the  b  2 integrin Mac-1, but not lymphocyte function-
associated antigen, and also involves the  a  4/ b  1 integrin 
(CD49d/CD29).  43  Neutrophil killing of pneumococci 
does not require NADPH oxidase-dependent gener-
ation of ROS but is dependent on the generation 
of the neutrophil serine proteases cathepsin G and 
neutrophil elastase.  44 , 45  In the absence of NADPH 
oxidase-generated ROS, mice tolerate greater numbers 
of neutrophils in the lung without a concomitant 
increase in lung injury.  46  
 In addition to modulation of neutrophil recruit-
ment or generation of antimicrobial molecules, the 
neutrophilic inﬂ ammatory response might also be 
modulated by manipulation of the cytokine network. 
Deletion of myeloid-expressed phosphatase and tensin 
homolog deleted on chromosome 10 enhances mac-
rophage phagocytosis and killing of pneumococci. 
Deletion of phosphatase and tensin homolog deleted 
  
 Figure 3.  Critical elements in the host response to Spn. AMs can 
phagocytose Spn, and ingested bacteria are killed within phago-
lysosomes and by apoptosis-associated killing. When the capacity 
of AMs to clear Spn is overwhelmed, AMs cooperate with EC 
through the release of IL-1 and other cytokines to stimulate the 
release of CXC chemokines, which leads to PMN recruitment to 
clear bacteria.  40  The cell network also involves T cells and iNKT 
that aid bacterial clearance and can also regulate the neutrophilic 
inﬂ ammatory response.  41 , 42  Th17 T cells aid neutrophil recruit-
ment in particular in the upper airway via release of IL-17A.  14  
iNKT  5 invariant natural killer T cell. See Figure 1 legend for 
expansion of other abbreviations. 
on chromosome 10 also reduces proinﬂ ammatory cyto-
kine production and neutrophil recruitment, result-
ing in reduced lung injury and improved survival with 
pneumococcal pneumonia.  47  Turning off proinﬂ am-
matory cytokine responses at the appropriate time is 
also key to ensuring the appropriate resolution of 
neutrophilic inﬂ ammation. For example, an impor-
tant role for triggering receptor expressed on myeloid 
cells-1 has emerged in both amplifying early inﬂ am-
matory responses but also downregulating the later 
phase of the inﬂ ammatory response via upregulation 
of IL-1R-associated kinase M, a negative regulator 
of TLR signaling.  48  Matrix metalloproteases 2 and 
9 cleave IL-17A, also reducing neutrophil recruitment 
to the lung.  49  
 A further critical part of the resolution phase of 
pneumococcal pneumonia is the clearance of apo-
ptotic neutrophils by macrophage efferocytosis. In 
addition to enhancing neutrophil function, galectin 
3 enhances macrophage efferocytosis and ensures less 
lung damage arises during pneumococcal pneumonia.  50  
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The manipulation of neutrophilic inﬂ ammation is an 
important goal because a subset of individuals with 
pneumococcal pneumonia die with a dysregulated 
inﬂ ammatory response despite complete clearance of 
bacteria. 
 The Role of T Cells in Pneumonia 
Pathogenesis 
 The adaptive arm of the immune response is also 
critical to the host response to pneumococci. B cells 
are critical for antibody responses to naturally occur-
ring infection and immunization, but review of their 
role is beyond the scope of this article. T cells contri-
bute to the pathogenesis of pneumococcal pneumonia. 
T-cell numbers increase in the peribronchiolar region 
early during the evolution of pneumonia.  43  Never-
theless, the exact role of T cells in pneumococcal 
pneumonia has been debated. Recent experiments 
suggest that CD4  1  T-cell numbers or activation may 
adversely impact the cytokine network and survival 
during pneumococcal pneumonia.  51  Conversely, CD8  1  
T cells may play an important role, regulating Th17 
T-cell numbers in the lung, production of CXC 
chemokines, and neutrophil recruitment, and in their 
absence, survival is impaired during pneumococcal 
pneumonia.  52  Nevertheless, a certain level of CD4  1  
T-cell responsiveness is required for an optimal response 
to pulmonary pneumococci in many settings; Th17 
responses improved bacterial clearance in immunized 
mice  53  and monocytes primed Th1/Th17 responses 
to pneumococci via IL-12 production.  54  These ﬁ nd-
ings suggest that the composition and activation state 
of T-cell populations must be tightly regulated in 
the early stages of pneumonia to maximize bacterial 
clearance but to ensure that the inﬂ ammatory response 
is kept to a minimum. Invariant natural killer T cells 
are also emerging as contributing to the host response 
to pneumococci and, following IL-12 or glycolipid-
driven activation, contribute to IFN- g production and 
bacterial clearance, enhancing early microbial clear-
ance and limiting inﬂ ammation.  41 , 42  
 Perspective 
 The ongoing evolution of pneumococci will continue 
to challenge immunization protocols. An improved 
understanding of how early immune responses can 
be enhanced and how neutrophilic inﬂ ammation can 
be more tightly regulated will lead to the develop-
ment of more rational therapeutic strategies. In order 
for this to occur, the wealth of information derived 
from basic science and animal studies needs to be 
translated to patient groups, and novel therapeutic 
approaches manipulating the host response must be 
developed, building on these ﬁ ndings. Areas of atten-
tion should include building a more accurate molecular 
understanding of the basis of susceptibility. This can 
be achieved through application of ﬁ ndings relating 
to the early steps in the immune response to subclin-
ical infection and the early stages of pneumonia. Such 
knowledge could be used to better stratify patients 
who are at risk for enhanced immunization programs 
or other preventive strategies. In addition, a better 
understand ing of the core components of a successful 
inﬂ ammatory response to pneumococcal pneumonia 
is needed. This can inform therapeutic approaches 
that maximize bacterial clearance but minimize the 
inﬂ ammatory consequences both to the lung and sys-
temically. These aims may seem aspirational, but the 
constant evolution of the pneumococcus demands 
that we develop innovative approaches to combat a 
major global cause of medical illness. 
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